Project cooperationUpdated on 27 November 2025
New in vitro assay methodologies
Seinor research scientist at SINTEF Industry
Trondheim, Norway
About
To be able to better predict the safety and efficacy of drugs, including advanced therapies (e.g. mRNA therapies, immune therapies), and at the same time account for the requirement for multiple parallel testing and throughput, we are designing 2D and 3D cell models from cell lines, primary cells, stem cells and patient-derived tissues, tailored to specific applications.
We are in particular interested in applying models for sex- and hormone-differentiated screening, to enable prediction of sex- and gender-dependent differences in drug safety and effect.
We have demonstrated ability of our cell models to be used for machine learning model building, as well as for verifying AI-predicted drug effects.
We are looking for: partners with relevant complementary expertise to join consortia and develop project together
Topic
- DESTINATION 5: HORIZON-HLTH-2026-01-TOOL-03: Integrating New Approach Methodologies (NAMs) to advance biomedical research and regulatory testing
Organisation
Similar opportunities
Project cooperation
Methods to assess sex, hormone, genetic, and physiologic population differences
- Consortium/Coordinator seeks Partners
- Partner seeks Consortium/Coordinator
- DESTINATION 1: HORIZON-HLTH-2026-01-STAYHLTH-03: Building public trust and outreach in the life sciences
- DESTINATION 5: HORIZON-HLTH-2026-01-TOOL-03: Integrating New Approach Methodologies (NAMs) to advance biomedical research and regulatory testing
- DESTINATION 3: HORIZON-HLTH-2026-01-DISEASE-11: Understanding of sex and/or gender-specific mechanisms of cardiovascular diseases: determinants, risk factors and pathways
Torkild Visnes
Senior scientist at SINTEF Industry
Trondheim, Norway
Project cooperation
Allogeneic Cell therapy of cancer an autoimmune diseases
- DESTINATION 6: HORIZON-HLTH-2026-01-IND-03: Regulatory science to support translational development of patient-centred health technologies
- DESTINATION 5: HORIZON-HLTH-2026-01-TOOL-03: Integrating New Approach Methodologies (NAMs) to advance biomedical research and regulatory testing
- DESTINATION 5: HORIZON-HLTH-2026-01-TOOL-07: Establishing a European network of Centres of Excellence (CoEs) for Advanced Therapies Medicinal Products (ATMPs)
- DESTINATION 4: HORIZON-HLTH-2026-01-CARE-01: Public procurement of innovative solutions for improving citizens' access to healthcare through integrated or personalised approaches
- DESTINATION 5: HORIZON-HLTH-2026-01-TOOL-06: Support to European Research Area (ERA) action on accelerating New Approach Methodologies (NAMs) to advance biomedical research and testing of medicinal products and medical devices
- DESTINATION 3: HORIZON-HLTH-2026-01-DISEASE-09: Multisectoral approach to tackle chronic non-communicable diseases: implementation research maximising collaboration and coordination with sectors and in settings beyond the healthcare system (GACD)
Cristina Maccalli
Principal Investigator at IRCCS Azienda Ospedaliera Metropolitana, plesso Ospedale Policlinico San Martino
Genova, Italy
Project cooperation
Digital Twin–Guided Development of Stem Cell Organoids for Disease Modeling and Tissue Repair
- Consortium/Coordinator seeks Partners
- DESTINATION 6: HORIZON-HLTH-2026-01-IND-03: Regulatory science to support translational development of patient-centred health technologies
- DESTINATION 5: HORIZON-HLTH-2026-01-TOOL-03: Integrating New Approach Methodologies (NAMs) to advance biomedical research and regulatory testing
Ahmed Morsy
Assistant Professor at Konkuk university
Seoul, South Korea